Evidence map›Paper›PMID 24827118›Full record

SynthesisPloS one2014

Prognostic value of tumor-infiltrating FoxP3+ T cells in gastrointestinal cancers: a meta analysis.

Yong Huang, Huaiwei Liao, Yong Zhang, Rongfa Yuan, Fengmei Wang, Yingtang Gao, Peng Wang, Zhi Du

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. PD-L1Technology in cancer research & treatment
    Trial
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yong HuangTianjin Medical University, Tianjin, China; Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Huaiwei LiaoDepartment of plastic surgery, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Yong ZhangTianjin Medical University, Tianjin, China.
Rongfa YuanDepartment of Hepatobiliary Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Fengmei WangDepartment of Gastroenterology and Hepatology, The Third Central Hospital of Tianjin, Tianjin, China.
Yingtang GaoKey Laboratory of Artificial Cell, Institute of Hepatobiliary Disease, The Third Central Hospital of Tianjin, Tianjin, China.
Peng WangKey Laboratory of Artificial Cell, Institute of Hepatobiliary Disease, The Third Central Hospital of Tianjin, Tianjin, China.
Zhi DuKey Laboratory of Artificial Cell, Institute of Hepatobiliary Disease, The Third Central Hospital of Tianjin, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTumor-infiltrating FoxP3+ T cells have been reported in various human tumors, which impaired cell-mediated immunity and promoted disease progression. However, its prognostic value for survival in patients with different gastrointestinal cancers [hepatocellular carcinoma (HCC), colorectal cancer (CRC), gastric cancer (GC)] remains controversial.

methodsRelevant literature was searched using PubMed, Embase, Cochrane, Ovid Medline and Chinese wanfang databases. A meta-analysis was conducted to estimate pooled survival and recurrence ratios. The odds ratio (OR) and 95% confidence intervals (CI) were calculated employing fixed- or random-effects models depending on the heterogeneity of the included trials.

resultsFor HCC and GC, the overall survival at 1, 3 and 5-year of high FoxP3+ T cells infiltration patients were lower than low FoxP3+ T cells infiltration patients (P<0.05). The recurrences at 1, 3 and 5-year of high FoxP3+ T cells infiltration patients were higher than low FoxP3+ T cells infiltration patients (P<0.001). But for CRC, the overall survival at 1, 3 and 5-year of high FoxP3+ T cells infiltration patients were higher than low FoxP3+ T cells infiltration patients (P<0.001). There were no differences in 1, 3 and 5-year recurrences between high and low FoxP3+ T cells infiltration patients (P>0.05).

conclusionsOur findings suggested that tumor-infiltrating FoxP3+ T cells were a factor for a poor prognosis for HCC and GC, but a good prognosis for CRC.

Indexed as

Carcinoma, HepatocellularColorectal NeoplasmsFemaleForkhead Transcription FactorsGene ExpressionHumansLiver NeoplasmsLymphocytes, Tumor-InfiltratingMaleNeoplasm Recurrence, LocalOdds RatioPrognosisStomach NeoplasmsSurvival AnalysisForkhead Transcription FactorsFOXP3 protein, human

Identifiers

PMID24827118
PMCPMC4020764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.